Background FOLFIRINOX has increased efficacy but also toxicity. Despite various modified
FOLFIRINOX regimens, how much reduction is acceptable remains unclear. This study …

Pancreatic cancer is one of the most lethal of all malignancies. One of the reasons for the
dismal prognosis is that most diagnoses are made when the disease is either locally …

Pancreatic cancer is a highly aggressive malignancy with a poor prognosis. Over the past
decade, significant therapeutic advancements have improved the survival rates of patients …

AIM To directly compare the efficacy and toxicity of standard-dose FOLFIRINOX
(sFOLFIRINOX) and modified-dose FOLFIRINOX (mFOLFIRINOX, 75% of standard-dose) for …

Objective A network meta‐analysis was conducted to compare the efficacy and toxicity of
different chemotherapy regimens in treating advanced or metastatic pancreatic cancer (PC) …

Background/Aim: The regimen of nanoliposomal irinotecan plus 5-fluorouracil and
leucovorin (Nal-IRI/FL) was approved in Japan as second-line chemotherapy after …

Borderline resectable pancreatic cancer (BRPC) is a potentially resectable disease but is
associated with poorer survival compared to primary resectable disease. There has been no …

Objective The coronavirus disease (COVID-19) pandemic has altered the delivery of
medical care. The present study evaluated the impact of COVID-19 on the outcomes of …

Abstract Background FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, leucovorin)
treatment significantly improved overall survival in the recent phase III study and became a …

Background/Aim: Neutralization of the acidic tumor microenvironment, which is associated
with both progression and drug resistance of cancer cells, may be a new treatment option for …